Telomir Pharmaceuticles

Across IND-enabling GLP safety studies conducted to date, Telomir-1 (Telomir-Zn) has been well tolerated, with no treatment-related adverse or dose-limiting toxicities observed. The GLP safety package includes cardiovascular telemetry, respiratory assessment, repeat-dose toxicology in rats and dogs, and phototoxicity evaluation. Across studies, systemic exposure was consistent following oral administration, supporting predictable pharmacokinetic behavior. These data supported IND clearance by the FDA and advancement into first-in-human clinical development. Follow along for continued clinical and regulatory updates. #GLPSafety #TelomirZn #IND #ClinicalDevelopment #PreclinicalData #Biotech

#NEWS We're happy to announce the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for our lead program, Telomir-Zn, in Triple-Negative Breast Cancer (TNBC), an aggressive cancer lacking estrogen, progesterone, and HER2 receptors, making it unresponsive to hormone therapies or HER2-targeted drugs. The clearance of our IND, including the Phase 1/2 clinical protocol, marks a tremendously important step for Telomir as we advance Telomir-Zn into clinical evaluation. We invite everyone to follow along with our story as we look to tackle one of the most aggressive types of breast cancer as it has historically been difficult to treat, accounting for approximately 15% of all breast cancers. Read the full press release here: ir.telomirpharma.com/telomir-pharma…

Telomir Pharmaceuticals (Nasdaq: TELO) is excited to participate in the AACR Annual Meeting 2026 in San Diego, CA. We will be presenting preclinical data on Telomir-1 (Telomir-Zn), our first-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways in advanced and metastatic Triple-Negative Breast Cancer (TNBC). Our IND has been submitted to the FDA, and we are preparing to initiate a Phase 1/2 clinical trial. Patients with TNBC face limited durable treatment options. Telomir-Zn takes a fundamentally different approach — addressing the biological mechanisms behind treatment resistance at the epigenetic level. We look forward to connecting with the cancer research community at AACR 2026 and other conferences. #TNBC #BreastCancer #Epigenetics #Oncology #AACR2026 $TELO

$TELO @TelomirPharma has submitted an IND application to the FDA for Telomir-1 in advanced & metastatic Triple-Negative Breast Cancer. A major milestone as we advance toward first-in-human clinical development. ir.telomirpharma.com/single-news-re… #Biotech #Oncology #TNBC #ClinicalTrials

$TELO Telomir-1 targets a fundamental driver of cellular dysfunction: intracellular metal imbalance. By reducing redox-active iron and increasing zinc, Telomir-1 helps restore epigenetic regulation—impacting DNA methylation, histone activity, and telomere stability. Iron drives oxidative stress and epigenetic disruption. Zinc supports genomic stability and proper gene expression. This is upstream biology—addressing root mechanisms in cancer and aging, not just downstream effects. Learn more: telomirpharma.com #Epigenetics #CancerResearch #BiotechInnovation

“Most people don't realize that many cancer immunotherapies are not effective for a large portion of solid tumor patients. Telomir is focused on addressing that gap. Telomir-1 targets tumor survival and cellular aging at the epigenetic level. This isn't an incremental improvement, it's a different approach entirely. This was never just a company. It was a commitment to the patients that existing medicine is still leaving behind.” $TELO | #Oncology #Biotech #DrugDevelopment #Epigenetics

$TELO Most oncology drugs target tumors directly. Few target what tumors depend on internally. Iron rescue attenuated the observed effect. That distinction matters. Full data in today’s release ⬇️ ir.telomirpharma.com/telomir-pharma… #Oncology #Biotech

$TELO Our recent human cell line data help clarify the mechanism underlying results we’ve previously reported in iron-dependent cancer models and age-associated biology. Understanding why something works — across oncology and aging — is as important as showing that it works. #Aging #Oncology ir.telomirpharma.com/telomir-pharma…

$TELO New animal data from Telomir Pharmaceuticals: Representative zebrafish TNBC tumor xenograft images showing primary tumor growth over time, comparing untreated control and Telomir-1–treated tumors. Full study results and context: ir.telomirpharma.com/telomir-pharma… #Biotech #Oncology #TripleNegativeBreastCancer

$TELO @TelomirPharma (NASDAQ: TELO) reported favorable IND-enabling GLP safety results for Telomir-1, with no treatment-related adverse toxicity observed across completed studies and consistent systemic exposure following oral administration. An important milestone as we continue regulatory preparation. ir.telomirpharma.com/single-news-re… #Biotech #DrugDevelopment #Aging #Oncology #IND #SafetyFirst

$TELO @TelomirPharma (NASDAQ: TELO) will participate in the 3rd International Conference on Women’s Health and Breast Cancer in Tokyo, organized by @Prezentis. Dr. Itzchak Angel will present on Telomir-1, drawing on previously reported preclinical TNBC laboratory findings, where Telomir-1 demonstrated a dose-dependent reduction in cancer cell viability through disruption of iron-dependent energy and mitochondrial pathways, as well as ongoing TNBC animal studies and recently disclosed IND-enabling GLP safety results, which showed no treatment-related adverse toxicity observed. We look forward to continued scientific engagement as we advance disciplined research in areas of significant unmet need. #Biotech #Oncology #TNBC #DrugDevelopment #Oncology $TELO

$TELO New preclinical data: Telomir-1 reduced PSA levels in human prostate cancer cells. PSA is a widely used biomarker associated with prostate cancer activity. These findings are consistent with results from a prior PC3 xenograft model, where Telomir-1 showed anti-tumor activity. In that study, paclitaxel—a commonly used chemotherapy drug—reduced tumor volume alone but was associated with mortality, while the paclitaxel + Telomir-1 combination showed full tumor-volume reduction with no mortality observed in that model. Telomir-1 is being developed to explore epigenetic and metabolic pathways linked to cancer biology. Research continues. ir.telomirpharma.com/single-news-re…

$TELO AML outcomes remain poor: ~30% 5-yr survival, with many patients unable to tolerate current toxic therapies. Today we reported Telomir-1 kills aggressive leukemia cells in vitro, aligned with our broader oncology research. Telomir-1 acts on intracellular iron + epigenetic dysregulation, key drivers of leukemia growth. Details: ir.telomirpharma.com/telomir-pharma… #Oncology #aging #DNA #Cancer

$TELO New Data: Telomir-1 dramatically reduces intracellular iron In a live-cell study, Telomir-1 showed a striking reduction of intracellular Fe²⁺ at just 1 μM — far greater than untreated cells. Why this matters👇 Excess iron inside cells fuels oxidative stress, DNA damage, mitochondrial decline & is increasingly linked to aging biology, cancer growth, and multiple age-related diseases. By helping rebalance intracellular metals, Telomir-1 targets one of the most fundamental processes that drive cellular deterioration. A picture says it all: #Biotech #AgingResearch #CancerResearch #Longevity #Epigenetics #IronBiology #DNA ir.telomirpharma.com/single-news-re…

$TELO: New preclinical data show Telomir-1 modulated two key defense genes — CASP8 (cell-death signaling) and GSTP1 (cellular detox). Findings add to evidence that Telomir-1 targets epigenetic pathways central to cancer biology. 🔗 ir.telomirpharma.com/single-news-re… #Epigenetics #biotech #DNA

$TELO Grateful for the feature by @PrismMarketView during #BreastCancerAwarenessMonth. Our work with Telomir-1 reflects a commitment to understanding and addressing the root causes of cancer — through the epigenetic and metabolic pathways that drive disease progression. #Biotech #Oncology #Epigenetics #CancerResearch

$TELO Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells. During #BreastCancerAwarenessMonth, we share new preclinical findings that highlight how understanding cancer at the epigenetic level may help reveal its vulnerabilities. Read more: ir.telomirpharma.com/single-news-re…

$TELO New cancer data: Telomir-1 resets DNA methylation of key tumor-suppressor genes linked to metastasis and treatment resistance in prostate cancer models. Read more 👉 ir.telomirpharma.com/single-news-re… $TELO #Oncology #Epigenetics #CancerResearch